Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Arvinas Holding Company ( (ARVN) ) just unveiled an announcement.
Arvinas, in collaboration with Pfizer, announced promising preliminary results from the Phase 1b TACTIVE-U sub-study evaluating the combination of vepdegestrant and abemaciclib in patients with advanced ER+/HER2- breast cancer. The study demonstrated a 62.5% clinical benefit rate, with no significant drug-drug interactions and a safety profile consistent with expectations, supporting the continuation into Phase 2 trials.
More about Arvinas Holding Company
Arvinas is a clinical-stage biotechnology company focused on developing protein degradation therapies to treat debilitating and life-threatening diseases. The company uses its PROTAC (PROteolysis Targeting Chimera) platform to develop investigational drugs like vepdegestrant for ER+/HER2- breast cancer, ARV-393 for non-Hodgkin Lymphoma, and ARV-102 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut.
YTD Price Performance: -39.07%
Average Trading Volume: 579,077
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.72B
See more data about ARVN stock on TipRanks’ Stock Analysis page.
